The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update.
 
Espen Basmo Ellingsen
Employment - Ultimovacs
Stock and Other Ownership Interests - Ultimovacs
Research Funding - Ultimovacs
 
Elin Aamdal
Honoraria - Bristol-Myers Squibb (Inst)
 
Else Marit Inderberg
Stock and Other Ownership Interests - Ultimovacs
Patents, Royalties, Other Intellectual Property - Ultimovacs; Zelluna
 
Wenche Rasch
Employment - Ultimovacs
Stock and Other Ownership Interests - Ultimovacs
 
Paal Brunsvig
No Relationships to Disclose
 
Steinar Aamdal
Employment - Ultimovacs
Stock and Other Ownership Interests - Ultimovacs
Honoraria - Bristol-Myers Squibb; Novartis
 
Eivind Hovig
Stock and Other Ownership Interests - NEC OncoImmunity AS; PubGene
 
Marta Nyakas
Consulting or Advisory Role - Incyte (Inst); MSD Oncology (Inst); Novartis (Inst)
 
Tormod Kyrre Guren
No Relationships to Disclose
 
Gustav Gaudernack
Employment - Ultimovacs
Leadership - Diatec AS; Zelluna
Stock and Other Ownership Interests - Ultimovacs
Patents, Royalties, Other Intellectual Property - Ultimovacs; Zelluna